Filing Flows › Rhythm Pharmaceuticals (RYTM) › Q3 2026 › vs Q3 2025
Rhythm Pharmaceuticals (RYTM) Q3 2026 vs Q3 2025 (year over year)
Rhythm Pharmaceuticals's revenue rose $40.8M (+80%) from $51.3M in Q3 2025 to $92.1M in Q3 2026.
Rhythm Pharmaceuticals, Q3 2026: revenue $92.1M (+80% year over year), operating margin -42.6%, net loss $41.4M, operating cash flow −$3.1M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $92.1M | $51.3M | $40.8M | +80% |
| Net loss | $41.4M | $52.9M | −$11.5M | -22% |
| Costs & expenses | $133M | $104M | $29.3M | +28% |
| Operating costs | $131M | $104M | $27.4M | +26% |
| Interest & other, net | $1.5M | $140K | $1.3M | +964% |
| Income tax | $610K | $111K | $499K | +450% |
| Cost of revenue | $12.2M | $5.5M | $6.7M | +121% |
| Research & development | $52.5M | $46.0M | $6.5M | +14% |
| SG&A | $66.8M | $52.4M | $14.3M | +27% |
| Operating cash sources | $41.4M | $52.9M | −$11.5M | -22% |
| Share-based compensation | $25.0M | $18.8M | $6.2M | +33% |
| Working capital & other | $13.3M | $7.5M | $5.8M | +78% |
| Cash used in operations | $3.1M | $26.6M | −$23.6M | -88% |
| Net loss absorbed | $41.4M | $52.9M | −$11.5M | -22% |
Questions
How much did Rhythm Pharmaceuticals's revenue grow year over year in Q3 2026?
Rhythm Pharmaceuticals's revenue rose $40.8M (+80%) from $51.3M in Q3 2025 to $92.1M in Q3 2026.